(Q37658876)

21 August 2017

1 reference

title

Perspectives for the development of human papillomavirus vaccines and immunotherapy (English)

1 reference

21 August 2017

1 reference

1 reference

2

Philippe Langella

1 reference

21 August 2017

author name string

Luis G Bermúdez-Humarán

series ordinal

1

1 reference

21 August 2017

publication date

1 January 2010

1 reference

Expert Review of Vaccines

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

35-44

1 reference

Role of Conformational Epitopes Expressed by Human Papillomavirus Major Capsid Proteins in the Serologic Detection of Infection and Prophylactic Vaccination

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Therapeutic vaccination for HPV induced cervical cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Prevention of cervical cancer through papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Papillomavirus vaccines in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Cervical cancer screening policies and coverage in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Developing an HPV vaccine to prevent cervical cancer and genital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Natural history and epidemiology of HPV infection and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Oral immunogenicity of human papillomavirus-like particles expressed in potato

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Mucosal immunity and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Normal structure, function, and histology of mucosa-associated lymphoid tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Immunostimulating complexes (ISCOMs) for nasal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Use of attenuated bacteria as delivery vectors for DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Nasal vaccination using live bacterial vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

A comparison of anionic nanoparticles and microparticles as vaccine delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Vaccination to prevent and treat cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

DNA vaccines: precision tools for activating effective immunity against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

CD8+ T-cell-mediated response to Listeria monocytogenes taken up in the liver and replicating within hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors im

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

Cancer incidence and mortality in France over the period 1980–2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.145

21 January 2018

Identifiers

DOI

10.1586/ERV.09.145

1 reference

21 August 2017

1 reference